Tscan Therapeutics is trading 11.76% higher at $0.21 in after-hours trading; no company-specific catalyst was confirmed. - That compares with the October 26 regular-session close of $0.19. Confidence is low, as no reliable report tied the move to a specific event. - The October 16 preliminary proxy filing proposed a potential reverse stock split but does not explain the rise. The broader market was mixed, and several recent declining closes do not explain the after-hours change.